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Introduction. In recent years, there has been an increase in the proportion of 
morbidity and mortality of population from chronic non-specific lung diseases 
(CNSLD) [1]. This is due to a number of reasons: air pollution, smoking, resistance 
of the bacterial flora to some antibiotics. A special attention of public health 
authorities to this problem is determined by the fact that the consequences of 
CNSLD, complicated by pulmonary heart disease (PHD), eventually lead to patients’ 
(primarily men) disability and death at able-bodied age (50-60 years) [2]. Thus, 
according to the WHO Expert Committee, more than half of patients with lung 
diseases develop PHD, which leads to frequent hospitalization. Statistics show that 
16-20% of all hospitalized subjects are PHD patients [3]. 
According to modern research findings, activation of lipid peroxidation is one 
of the leading links in PHD pathogenesis in chronic bronchitis [4]. 
The aim of our research was to study the dynamics of markers of lipid 
peroxidation (LPO) and antioxidant defense (AOD) in patients with chronic 
obstructive bronchitis (COB) and heart failure (HF) with myocardial hypertrophy and 
atrophy. 
Materials and methods. To solve the abovementioned tasks, we examined 62 
patients of both sexes with COB and HF, stage I-II. Each of them had at least 2 risk 
factors for COB (smoking, dustiness of the workplace, frequent colds, family 
history). Determination of nosological form of COB was carried out in accordance 
with the WHO criteria. The stage of circulatory failure was assessed in accordance 
with the classification by N.D. Strazhesko and V.Kh. Vasilenko. The diagnosis of 
COB was made on the basis of anamnestic, clinical and biochemical, instrumental 
data obtained by examining patients. 
30 patients (study group 1) with hypertrophy of the myocardium and 32 
patients with myocardial atrophy (study group 2) were examined. 
All patients underwent the following tests: total serum lipids, total cholesterol, 
β-lipoproteins, phospholipids, peroxide hemolysis of erythrocytes (PHE), malonic 
dialdehyde (MDA), superoxide dismutase (SOD), ceruloplasmin, catalase according 
to standard methods. 
Results. Our findings indicate that in both groups of patients, the total lipids, 
cholesterol, and β-lipoproteins in the blood were significantly increased. Studies of 
LPO in these groups of patients showed an increase of MDA in both groups of 
patients, but in the group with myocardial atrophy these rates were significantly 
higher than in the group with hypertrophy (14.34 ± 0.28 μmol / l and 10.67 ± 0.55 
μmol / l, respectively). The increase in peroxide hemolysis of erythrocytes was also 
more manifested in the group with myocardial atrophy (19.38 ± 1.05%) than in the 
group with hypertrophy (14.11 ± 0.89%). A statistically significant (p<0.05) decrease 
in catalase activity in the group with myocardial atrophy (2.11 ± 0.07) was also 
revealed. From the data obtained it follows that a greater activation of LPO was noted 
in the group with myocardial atrophy. This can be associated with the release of pro-
oxidant factors from the destroyed cardiomyocytes. 
Conclusion. Thus, the change in LPO markers indicates its significant 
activation in the development of myocardial atrophy, which makes it possible to 
consider the activation of LPO as one of the leading mechanisms in the development 
of this particular form of PHD in patients with CNSLD. 
Prospects for further research. The obtained results are the basis for the 
development and application of schemes for the diagnosis and treatment of PHD in 
patients with CNSLD, focused on antioxidant therapy. 
Recommendations. It is advisable to use LPO markers to evaluate the course 
of CNSLD with PHD. 
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